QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module VIII: When Is a PASS Needed?

Test your understanding of the concepts covered by GVP Module VIII: When Is a PASS Needed?.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which characteristic best describes fit-for-purpose evidence generation?

Using the most advanced design regardless of the question Choosing a design that matches the causal question, data availability, feasibility, bias and precision requirements Avoiding existing data because prospective collection is always stronger Prioritising study size over outcome validity

Question 2 of 10 A team wants to determine whether a medicine has a higher risk of an event than an alternative treatment. Which issue becomes particularly important in selecting and designing the study?

Whether the study uses only spontaneous reports Comparator selection and control of confounding Whether the study avoids defining the outcome in advance Whether the study is labelled voluntary

Question 3 of 10 What should be the starting point when deciding whether to conduct a PASS?

Selection of the most sophisticated available study design Identification of the exact safety or risk-management question Confirmation that the product has an important risk Preparation of a protocol before reviewing existing evidence

Question 4 of 10 What level of involvement is most appropriate for the QPPV in relation to significant PASS activity?

The QPPV must personally perform every study task The QPPV needs sufficient visibility and assurance over rationale, obligations, milestones, significant issues and integration of results into pharmacovigilance The QPPV is involved only after the final report The QPPV has no role in voluntary PASS because it is not imposed

Question 5 of 10 Which documentation would provide the strongest defensible rationale for rejecting a proposed PASS?

A statement that the study would be expensive A record linking the safety question, existing evidence, residual uncertainty, alternatives considered and reasons the alternatives are adequate An informal email stating that routine PV is preferred A protocol for a different safety concern

Question 6 of 10 An authority requires a non-interventional study as a condition of a marketing authorisation. How should the MAH primarily classify and manage the study?

As a voluntary research project with optional reporting As an imposed PASS and regulatory obligation As routine pharmacovigilance because it is non-interventional As a registry unrelated to pharmacovigilance commitments

Question 7 of 10 Which feature most fundamentally distinguishes a PASS from any study conducted after marketing authorisation?

It is conducted exclusively by the marketing authorisation holder It has a defined safety or risk-management purpose within the EU pharmacovigilance framework It must always use prospective data collection It must be conducted only after a safety signal has been confirmed

Question 8 of 10 What is the most accurate interpretation of a voluntary PASS?

It is exempt from scientific justification and quality controls It is initiated by the MAH because additional evidence is scientifically useful, although not imposed It can only address administrative questions It cannot be included in the RMP

Question 9 of 10 What is the correct relationship between an important risk and the need for a PASS?

An important risk automatically mandates a PASS An important risk is irrelevant to PASS decisions An important risk prompts assessment of whether further evidence is needed An important risk can only be addressed through spontaneous reports

Question 10 of 10 Which question is most likely to require an epidemiological PASS rather than relying solely on spontaneous reports?

Whether an individual case contains missing clinical details Whether a suspected signal should receive initial medical review What is the incidence of an adverse event among exposed patients Whether a published article should be included in literature surveillance

QPPV.com

GVP Module VIII: When Is a PASS Needed?

Cookie Settings